Biomedical Research Teams Foster Innovation with New XSeed Labs in the U.S.

XSeed Labs, a joint initiative by BioMed X and Boehringer Ingelheim, has initiated the operation of its initial research team located at Boehringer Ingelheim’s headquarters in Ridgefield, Connecticut. The primary focus of this team is to produce sophisticated models to better understand and treat wound healing and fibrosis.

Under the guidance of Dr. Lorenzo Talà, this new team aims to construct physiologically accurate disease models using both in vitro and in silico techniques, to further investigate fibrotic diseases, enhancing drug safety assessment and development processes.

Christian Tidona, BioMed X's founder, emphasized the continuity and growth of their innovative collaboration model. According to Carine Boustany, research head at Boehringer Ingelheim, this partnership will also focus on accelerating innovation pertaining to fibrotic diseases, leveraging significant research infrastructure to transform treatment solutions.